Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5204681
Max Phase: Preclinical
Molecular Formula: C201H270N48O53S7
Molecular Weight: 4431.12
Associated Items:
ID: ALA5204681
Max Phase: Preclinical
Molecular Formula: C201H270N48O53S7
Molecular Weight: 4431.12
Associated Items:
Canonical SMILES: CCCC[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H]2CSCCC(=O)N3CN(CN(C3)C(=O)CCSC[C@@H](C(=O)N[C@@H](CNC(=O)CCc3cn(CC(=O)N[C@H]4CSCCC(=O)N5CN6CN(C5)C(=O)CCSC[C@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc5cccc7ccccc57)NC(=O)[C@@H]5CCCN5C4=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc4c[nH]c5ccccc45)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N4CCC[C@H]4C(=O)N4C[C@H](O)C[C@H]4C(=O)N[C@@H](Cc4c[nH]c5ccccc45)C(=O)N[C@H](C(N)=O)CSCCC6=O)nn3)C(N)=O)NC1=O)C(=O)CCSC[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N2
Standard InChI: InChI=1S/C201H270N48O53S7/c1-10-11-37-128-174(277)231-148(100-308-76-63-162(262)241-105-238-104-240(106-241)161(261)62-75-307-99-147(187(290)218-132(78-112-29-13-12-14-30-112)176(279)210-108(2)171(274)226-140(87-167(270)271)195(298)245-67-25-43-152(245)191(294)222-133(177(280)215-128)79-113-46-51-120(253)52-47-113)232-178(281)134(80-114-48-53-121(254)54-49-114)223-190(293)150-41-24-66-244(150)194(297)109(3)211-172(275)130(55-57-164(264)265)217-189(292)151-42-26-68-246(151)196(299)141(88-201(6,7)8)227-185(288)145(212-111(5)252)97-305-73-60-159(238)259)188(291)228-142(169(202)272)91-209-156(256)56-50-119-92-243(236-235-119)94-157(257)213-149-101-309-77-64-163(263)242-103-237-102-239(107-242)160(260)61-74-306-98-146(233-183(286)139(86-166(268)269)221-179(282)135(224-192(295)153-44-27-69-247(153)197(149)300)81-116-33-23-32-115-31-15-16-34-123(115)116)186(289)216-131(58-71-303-9)175(278)214-129(40-21-22-65-206-200(204)205)173(276)220-138(85-165(266)267)182(285)219-136(82-117-89-207-126-38-19-17-35-124(117)126)180(283)229-143(95-250)184(287)234-168(110(4)251)199(302)248-70-28-45-154(248)198(301)249-93-122(255)84-155(249)193(296)225-137(83-118-90-208-127-39-20-18-36-125(118)127)181(284)230-144(170(203)273)96-304-72-59-158(237)258/h12-20,23,29-36,38-39,46-49,51-54,89-90,92,108-110,122,128-155,168,207-208,250-251,253-255H,10-11,21-22,24-28,37,40-45,50,55-88,91,93-107H2,1-9H3,(H2,202,272)(H2,203,273)(H,209,256)(H,210,279)(H,211,275)(H,212,252)(H,213,257)(H,214,278)(H,215,280)(H,216,289)(H,217,292)(H,218,290)(H,219,285)(H,220,276)(H,221,282)(H,222,294)(H,223,293)(H,224,295)(H,225,296)(H,226,274)(H,227,288)(H,228,291)(H,229,283)(H,230,284)(H,231,277)(H,232,281)(H,233,286)(H,234,287)(H,264,265)(H,266,267)(H,268,269)(H,270,271)(H4,204,205,206)/t108-,109+,110+,122+,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139+,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,168-/m0/s1
Standard InChI Key: FKSNUQRGVHJZFC-RANFTAKUSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 4431.12 | Molecular Weight (Monoisotopic): 4427.7953 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Upadhyaya P, Kristensson J, Lahdenranta J, Repash E, Ma J, Kublin J, Mudd GE, Luus L, Jeffrey P, Hurov K, McDonnell K, Keen N.. (2022) Discovery and Optimization of a Synthetic Class of Nectin-4-Targeted CD137 Agonists for Immuno-oncology., 65 (14.0): [PMID:35819182] [10.1021/acs.jmedchem.2c00505] |
Source(1):